(VIANEWS) – COVIVIO HOTELS (COVH.PA), ALTAREA (ALTA.PA), MEDISTIM (MEDI.OL) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio as yet. The payout ratio in itself isn’t a promise of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. COVIVIO HOTELS (COVH.PA)
325% Payout Ratio
Covivio Hotels specializes in owning business premises in the hotel sector. A listed real estate investment company (SIIC), a real estate partner of the major players in the hotel industry, Covivio Hotels holds assets worth EUR 6.4 billion (at end 2023). Covivio Hotels is graded BBB+ / Stable outlook by Standard and Poor's.
Earnings Per Share
As for profitability, COVIVIO HOTELS has a trailing twelve months EPS of €-0.08.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.53%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Apr 17, 2024, the estimated forward annual dividend rate is 1.3 and the estimated forward annual dividend yield is 7.22%.
More news about COVIVIO HOTELS.
2. ALTAREA (ALTA.PA)
188.32% Payout Ratio
Altarea is the French leader in low-carbon urban transformation, with the most comprehensive real estate offering to serve the city and its users. In each of its activities, the Group has all the expertise and recognised brands needed to design, develop, market and manage tailor-made real estate products. Altarea is listed in compartment A of Euronext Paris.
Earnings Per Share
As for profitability, ALTAREA has a trailing twelve months EPS of €-21.02.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -14.17%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 15.5%, now sitting on 2.58B for the twelve trailing months.
More news about ALTAREA.
3. MEDISTIM (MEDI.OL)
78.95% Payout Ratio
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Europe, Asia, and internationally. The company offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and TTFM in a single system for vascular surgery; MiraQ Ultimate that combines TTFM and ultrasound imaging in a single system for cardiac, vascular, and transplant surgery; and imaging probes for intraoperative use. It also provides QuickFit TTFM probes, which is designed to hold the vessel and ensure precise measurements on various types of vessel grafts; Vascular TTFM probes for locking slide mechanism designed to secure the vessel while minimizing the manipulation of fragile or calcified vessels; and Doppler probes that are used to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, the company distributes and sells third party medical equipment. Medistim ASA was founded in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr5.71.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 28.28. Meaning, the purchaser of the share is investing kr28.28 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.31%.
Moving Average
MEDISTIM’s worth is under its 50-day moving average of kr168.05 and way under its 200-day moving average of kr190.93.
Volume
Today’s last reported volume for MEDISTIM is 64750 which is 545.24% above its average volume of 10035.
More news about MEDISTIM.
4. RUBIS (RUI.PA)
56.14% Payout Ratio
Rubis engages in the operation of bulk liquid storage facilities for commercial and industrial customers in Europe, Africa, and the Caribbean. The company operates through Energy Distribution and Renewable Electricity Production segments. It is involved in the bulk liquid storage of fuels, biofuels, chemicals, and agrifood products; and retails and distributes fuels, heating oils, lubricants, liquefied gases, and bitumen, as well as provides logistics services comprising trading-supply, refining, and shipping activities. The company also engages in the production of photovoltaic electricity; provision of car wash services; and operation of convenience stores and quick-service restaurants across various service stations operated under the RUBiS and ViTO brands. It serves transportation, infrastructure, hotel, aviation, marine, and public works sectors. Rubis was incorporated in 1954 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, RUBIS has a trailing twelve months EPS of €3.42.
PE Ratio
RUBIS has a trailing twelve months price to earnings ratio of 9.57. Meaning, the purchaser of the share is investing €9.57 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.05%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 14%, now sitting on 6.63B for the twelve trailing months.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jun 14, 2024, the estimated forward annual dividend rate is 1.98 and the estimated forward annual dividend yield is 6.86%.
More news about RUBIS.
5. VALUE8 (VALUE.AS)
31.58% Payout Ratio
Value8 N.V. is a private equity firm specializing in middle market, buyout, add-on and growth capital investments in small and medium-sized companies. The firm primarily invests in the food, healthcare, business and financial services, energy, safety and security, water and environment, leisure, luxury products and internet sectors. It typically invests in Western Europe, primarily in the Netherlands, Belgium and France. The firm considers investments in companies with an enterprise value between €10 million ($10.74 million) and €150 million ($208.87 million). The firm prefers to take a seat on the board of directors and seeks to exit the investment through a public listing. Value8 NV was founded in 2008 and is headquartered in Bussum, Netherlands.
Earnings Per Share
As for profitability, VALUE8 has a trailing twelve months EPS of €1.28.
PE Ratio
VALUE8 has a trailing twelve months price to earnings ratio of 4.53. Meaning, the purchaser of the share is investing €4.53 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.16%.
Yearly Top and Bottom Value
VALUE8’s stock is valued at €5.80 at 17:10 EST, under its 52-week high of €6.10 and above its 52-week low of €5.35.
More news about VALUE8.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of €1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing €1 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
More news about 1.
